Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumors
We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in “Cookie Settings”.